Immutep (ASX:IMM) will present new clinical results from its AIPAC-003 Phase 2 trial at next week’s San Antonio Breast Cancer Symposium, highlighting encouraging response rates and clear signs of immune activation in heavily pretreated metastatic breast cancer patients. …
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 Australian Biotech
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News